PrecisionBiotics (PB) is an innovative Irish healthcare company and a global pioneer in discovery, development and commercialisation of proprietary probiotic and pharmabiotic treatments. Our new and breakthrough scientific research is recognised around the world as being at the cutting edge of discovery and application. Alimentary Health, the research function of PB, is the foundation industry partner of the Alimentary Pharmabiotic Centre based at University College Cork, Ireland. An international business, PB is centred on targeting health indications and exploiting applications arising from its core probiotic strains and derivatives via: - Basic and applied research into novel applications - Research partnerships in applications for Food, Food Supplement, Medical Food and Rx products - Marketing of a range of proprietary brands for the clinical and consumer markets PB's mission is to develop clinically supported probiotic healthcare and nutritional products that health professionals can believe in. The company focuses on isolation, characterization, clinical evaluation and formulation of probiotics and their actives for inflammatory and infectious conditions, reflecting our expertise in gastroinestinal medicine, the brain-gut axis, metabolic health and nutrition. Since 1999, approximately 150 peer reviewed publications on PB’s strains have been published, many of which have been influential in understanding the benefits of probiotics. In fact, two key scientific papers detailing the clinical work of PB’s lead strain Bifidobacterium infantis 35624 in Irritable Bowel Syndrome have been cited more than 1,000 times in scientific literature since their publication.